A major deal for pharmaceuticals company DuoCort

DuoCort AB har ingått avtal med läkemedelsföretaget ViroPharma Incorporated om att sälja dotterbolaget DuoCort Pharma AB med dess egenutvecklade läkemedel Plenadren®, en ny behandling för binjurebarksvikt, även kallad Addisons sjukdom. Det totala avtalsvärdet uppgår till över en miljard kronor varav 220 miljoner erhålls i samband med ViroPharmas förvärv av DuoCort Pharma.

Positive Opinion from CHMP for Plenadren

The Swedish specialty pharma company, DuoCort Pharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending marketing authorisation of its product Plenadren, a novel treatment for adrenal insufficiency.

Positive clinical data for new prostate cancer treatment

LIDDS new local treatment of prostate cancer shows a clear local antiandrogen response and is well tolerated. The Swedish pharmaceutical company presented interim data from its phase IIa trial at the 26th Annual Congress of the European Association of Urology (EAU) in Vienna this weekend.

Share this page

Subscribe

Read more about our Protection of your personal data.